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Opportunistic dose amplification 
for proton and carbon ion therapy 
via capture of internally generated 
thermal neutrons
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This paper presents Neutron Capture Enhanced Particle Therapy (NCEPT), a method for enhancing the 
radiation dose delivered to a tumour relative to surrounding healthy tissues during proton and carbon 
ion therapy by capturing thermal neutrons produced inside the treatment volume during irradiation. 
NCEPT utilises extant and in-development boron-10 and gadolinium-157-based drugs from the related 
field of neutron capture therapy. Using Monte Carlo simulations, we demonstrate that a typical proton 
or carbon ion therapy treatment plan generates an approximately uniform thermal neutron field within 
the target volume, centred around the beam path. The tissue concentrations of neutron capture agents 
required to obtain an arbitrary 10% increase in biological effective dose are estimated for realistic 
treatment plans, and compared to concentrations previously reported in the literature. We conclude 
that the proposed method is theoretically feasible, and can provide a worthwhile improvement in 
the dose delivered to the tumour relative to healthy tissue with readily achievable concentrations of 
neutron capture enhancement drugs.
The principal aim of all forms of radiation therapy is to deliver the maximum therapeutic radiation dose to the 
target, while sparing surrounding healthy tissue. One of the greatest challenges of radiotherapy is to minimise 
its latent effects - including the risk of secondary cancer, which can occur anywhere from five years to many 
decades post-treatment1–4. The objective is to minimise normal tissue complication probability (NTCP) - which 
includes the probability of developing treatment-induced cancers - by maximising the conformity of the delivered 
dose to the target volume4,5. Technological advancements in radiotherapy such as intensity modulated radiother-
apy, image-guided radiotherapy and particle therapies have enabled more accurate and selective targeting of the 
tumour6. Many of these treatments can also be enhanced by the use of tumour-specific radiosensitisers, which 
increase the contrast between the biological dose delivered to the tumour and healthy tissues7.
Particle therapy is a form of radiotherapy in which a beam of highly energetic protons or heavy ions (most 
commonly carbon) is used to deliver a therapeutic radiation dose to a treatment region. Monoenergetic beams of 
protons and heavy ions exhibit a very well-defined Bragg peak, depositing most of their kinetic energy within a 
narrow energy-dependent depth range. By tuning the beam energy, this property enables the delivery of a highly 
conformal radiation dose distribution to the target. Particle therapy is therefore ideal for treatment of deep tis-
sues, since it results in a lower dose to healthy tissues in front of or behind the tumour compared to photon and 
electron beams6,8,9.
During particle therapy, most of the primary particles in the beam deposit their kinetic energy through mul-
tiple electromagnetic interactions with the target. However, a fraction of these particles will undergo nonelastic 
collisions with nuclei in the target. This results in the production of a range of nuclear fragments at the target site, 
including short-range, high-LET charged particles, and a mixture of fast and thermal neutrons. Due to scattering 
within the target tissue, the thermal neutrons are emitted nearly isotropically from the point of collision, and they 
deposit their energy in the region surrounding the path of the incident ion beam via a succession of elastic and 
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inelastic collisions10,11. The thermal neutrons irradiate both target and non-target tissues indiscriminately, and 
they deposit a fraction of the beam’s kinetic energy outside of the target volume9. Such interactions are typically 
regarded as a nuisance when they occur outside of the treatment region, since their existence undermines one 
of the main advantages of particle therapy - the large peak-to-entrance-plateau dose ratio. It is also important 
to emphasise that these thermal neutrons are generated internally - in the vicinity of the target area inside the 
patient. This is quite distinct from the neutrons which result from contamination of the beam due to collisions 
between the beam and beam modifying devices.
Light water, the principal constituent of human tissue, has a moderate thermal neutron cross-section (0.335 
barns12), which can be greatly increased by the introduction of agents containing isotopes such as 10B or 157Gd 
with very high neutron cross sections (3838 and 254000 barns, respectively13,14). While nonelastic thermal neu-
tron interactions with water primarily result in hydrogen capture of the neutron and the release of a high-energy 
gamma photon, nonelastic thermal neutron interactions with 10B and 157Gd result in the production of energetic 
charged particles with high relative biological effectiveness - the basic operating principle of neutron capture ther-
apy (NCT)15,16. Our central hypothesis is that if a sufficient thermal neutron fluence is generated during heavy ion 
therapy, it can be exploited therapeutically via the administration of a suitable non-toxic neutron capture agent 
containing 10B or 157Gd, preferentially absorbed by the tumour at an elevated concentration compared to the sur-
rounding normal tissue as in conventional NCT. This combined therapeutic modality is denoted neutron capture 
enhanced particle therapy (NCEPT). To validate our hypothesis, and demonstrate the feasibility of NCEPT, it is 
necessary to determine the concentrations of neutron capture agents which would be required to achieve a thera-
peutically significant boost to tumour dose during a typical proton or carbon ion treatment plan.
In conventional neutron capture therapy, the biological dose due to the presence of the capture agent depends 
on the physical dose (which, in turn, depends on the concentration of neutron capture agent), together with the 
relative biological effectiveness (RBE) of the secondary particles as determined by the specific neutron capture 
agent (NCA). The latter factor varies significantly between different cell types and context (i.e., in vitro vs. in vivo); 
it is also specific to each specific neutron capture agent. For this work, only values reported for in vivo studies are 
relevant. In BNCT literature this compound-specific RBE factor is commonly referred to as compound biological 
effectiveness (CBE), however most researchers working with gadolinium simply refer to it as RBE. For consistency 
we refer to it henceforth as CBE for both boron and gadolinium.
In the case of 10B, the capture mechanism results in the production of several high LET products17:
α γ+ → → + + .⁎nB [ B] Li (2 31 MeV) (1)th
10 11 7
Both the alpha particles and the lithium ions produce closely spaced ionisations in the immediate vicinity of the 
reaction, with a range of approximately 5–9 μm; this is approximately the diameter of the target cells18,19.
For the most widely used 10B-based neutron capture agent, 10B-4-borono-L-phenylalanine (10B-BPA), CBE 
values of 3.6–3.8 and 0.9–1.3 have been reported for brain tumour cells and normal tissues, respectively, with 
tumour to healthy tissue concentration ratios between 5:1 and 8:116,20–23. An alternative capture agent, borocaptate 
sodium (BSH), has shown potential for NCT applications; the reported range of CBE is between 1.2 and 2.3 in 
brain tumours and 0.37 to 0.5 in normal tissues, although the uptake concentration ratio tends to be much lower 
than for BPA (1.2–3.5 in the brain)22,24,25. The specific values differ for other target tissues, with higher values of 
CBE reported for liver tumours for both agents (tumour:liver CBE values of 9.94/4.25 and 4.22/0.94, and concen-
tration ratios of 2.8/0.3 for BPA and BSH, respectively)26.
The 157Gd neutron capture reaction follows a somewhat different path, and results in the production of an 
excited 158Gd nucleus and a high-energy gamma ray:
γ+ → → + + .⁎nGd [ Gd] Gd 7 94 MeV (2)th
157 158 158
Upon relaxation of the excited state, internal conversion (IC) and low-energy Auger electrons are produced, the 
latter responsible for the majority of the useful therapeutic effects. Classified as a high-LET radiation, Auger elec-
trons travel only a very short distance (a few nanometers in tissue) before depositing their kinetic energy, making 
them very effective if the source is concentrated in immediate vicinity of a DNA molecule or vital organelles (such 
as mitochondria)27–32. A yield of 5 Auger electrons, 1.8 γ photons and 0.69 IC electrons and 1.0 recoil nucleus has 
been estimated for the thermal neutron capture reaction33,34.
A number of studies have utilised Monte Carlo simulations to quantify the macroscopic, microscopic and 
nanoscopic components of the dose delivered by Auger-emitting isotopes in order to estimate their correspond-
ing CBE. Humm et al. conducted a review of dosimetry of Auger electrons at DNA, subcellular and organ level, 
and recommended a CBE of 10 when the emitter is electrostatically bound to the DNA of the nucleus35. Fairlie 
performed a review of the radiation-weighted factors and RBEs of Auger-emitting isotopes, and recommended 
the adoption of CBEs of 5 and 20 for emitters of multiple Auger electrons incorporated within cells and DNA, 
respectively36. Cerullo et al. estimated the lineal energy distribution of Auger electrons within a 6 nm diameter 
cylinder (representing a DNA fragment) using the PENELOPE Monte Carlo simulation code, and obtained CBEs 
of 12.6, 6 and 1.5 where electrons are localised inside, on the surface and outside of the cylinder, respectively31.
157Gd is of great interest for neutron capture therapy due to its extremely high thermal neutron cross-section - 
the highest of any stable isotope. While free Gd3+ ion is highly toxic to organisms both in vitro and in vivo, che-
lated Gd3+ compounds can be used safely due to their physiological stability37. Very high cellular concentrations 
of gadolinium can be achieved in vitro without significant cytotoxicity (of the order of several thousand ppm)38,39. 
While gadolinium contrast agents such as Gd-DOTA and Gd-DTPA are approved for use in humans diagnosti-
cally, neither accumulates to significant concentration within the cell nucleus40. Amongst the experimental gad-
olinium compounds, motexafin-gadolinium (MGd) been proposed as a potential candidate for GdNCT37. It is a 
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tumour-specific radiosensitiser, and its combined use with whole-brain radiation therapy has reached Phase III 
clinical trials41. With a 70:1 tumour to healthy tissue uptake ratio, prolonged retention of gadolinium in vitro (up 
to 2 months) and 90% uptake in glioblastoma cell nuclei, it is a promising candidate for use in NCT37,42–44. Recent 
efforts towards the development of DNA and mitochondria-targeting gadolinium agents has resulted in a number 
of promising agents. Morrison et al. have reported on the development of a tumour-cell selective mitochondrial 
agent designed for NCT applications, with cellular concentrations of up to 3000 ppm45,46.
Neutron capture radiotherapy based on 10B capture agents with external neutron beams is already an established 
radiotherapy modality, with traditional reactor-based neutron sources now being supplanted by more compact 
accelerator-based beam facilities. A number of accelerator-based epithermal neutron beam are in various stages of 
development and commissioning in hospitals in Japan, Finland, Russia, Taiwan, Argentina, Italy and the UK47–56. Two 
10B delivery agents, L − −p  boronophenylalanine (10B-BPA) and sodium mercaptoundecahydro-closo-dodecaborate 
(Na2 10B12H11SH; Na2 10B-BSH) have been used clinically to treat patients suffering from glioblastoma multiforme and 
malignant melanoma, with Phase II and III clinical trials for the treatment of glioblastoma (GBM), head and neck 
tumours and liver metastases underway in Japan, Finland, Sweden, Japan, Taiwan, and the United States57–65. However, 
treatment of tissues deeper than approximately 3 cm is challenging with external epithermal neutron beams, due to the 
very high neutron fluence at the surface which is required to achieve a therapeutic effect at the target - a consequence of 
the neutron-moderating effect of the water in human tissue66,67.
In this paper, the quantity and spatial distribution of the thermal neutron fluence generated by typical thera-
peutic scanned-beam proton and carbon ion irradiations of homogeneous PMMA targets has been estimated via 
Monte Carlo simulations. The tissue concentrations of several 10B and 157Gd-based NCAs required to achieve an 
arbitrary 10% boost to the tumour biological effective dose are calculated, and compared to tissue concentrations 
in different tissues previously reported in the literature, with the aim of demonstrating the feasibility of NCEPT.
Details of the Monte Carlo simulations, including the primary beam energy and geometry, phantoms and 
physical models, as well as the method used in the quantification of the neutron capture dose enhancement are 
presented in Section 2. Neutron fluence results and the estimated neutron capture dose enhancement for boron 
and gadolinium is presented in Section 3, with the implications for enhanced biological effective dose discussed 
in Section 4. Conclusions and proposed future work are presented in Section 5.
Materials and Methods
The method described here aims to establish whether NCEPT, when used in conjunction with a typical treatment 
plan, offers a significant therapeutic benefit compared to proton or heavy ion therapy alone. For the purpose 
of this study, significance is arbitrarily defined as an average 10% increase in photon-equivalent dose within 
the tumour resulting from the administration of a non-toxic bolus of neutron-capture agent; however, the 
method can be used with any desired dose increase factor. To answer this question, it is necessary to determine 
the concentration of neutron capture agent which is required in order to provide a 10% increase in effective 
photon-equivalent dose, for a simple simulated therapeutic proton/heavy ion treatment plan, and compare this 
with concentrations reported in the literature.
The first step is to evaluate the thermal neutron fluence (defined as neutrons with kinetic energy below 0.4 eV) 
resulting from pencil-beam irradiation of a point within a target volume. A set of simulations of this pencil beam, 
for both proton and 12C beams, is conducted with four different energies in a homogeneous PMMA target. Dose 
and thermal neutron fluence distributions are recorded for each simulation; corresponding distributions at ener-
gies in between these are also estimated by interpolating between the distributions obtained at these energies.
A simple treatment plan is then implemented, in which the pencil beam is stepped across an array of points 
inside a treatment volume at a series different energies. The primary particle fluence at each energy is then 
weighted such that a specified, approximately flat biological effective dose (BED) is delivered to a defined treat-
ment volume by the ion beam. Two 50 mm cubic volumes are evaluated, once centred at a depth of 125 mm and a 
second centred at a depth of 165 mm. Thermal neutron fluence distributions throughout the entire phantom are 
then estimated based on the primary particle fluence weights for each treatment volume.
Based on the thermal neutron fluence estimates obtained through this process, the concentrations of a number 
of 10B and 157Gd-based NCAs required to achieve a 10% increase in biological effective dose is then determined 
for each treatment volume. The resulting NCA concentrations in normal tissue (defined as the total phantom 
outside of the treatment volume) are calculated using the reported tumour to normal tissue ratios for these NCAs. 
Maximum additional dose delivered to normal tissue is then determined as a percentage increase in dose to nor-
mal tissue in excess of the dose delivered by the primary beam.
Simulation Parameters and Models. All Monte Carlo simulations were performed using the Geant4 
toolkit (version 10.2.p03)68,69. Electromagnetic interactions were modelled using the standard Geant4 physics 
option 3 model (G4EmStandardPhysics_option3), while the hadronic physics models used in the simulations are 
listed in Table 1.
A simple variance analysis method was used to determine the minimum number of primary particles to use 
in the simulations. A series of test simulations were conducted, each with M = 50 runs of =N k N( ) 2 ,k 0  
= ×N 1 100
5 primary particles. Thermal neutron fluence was calculated for each simulation within a test area 
centred on the Bragg peak, and the mean and standard deviation (SD) calculated across the M simulations. The 
inter-run standard deviation should approach zero as N k( ) tends to infinity; therefore, the experiment was 
repeated with progressively larger values of k until the ratio of inter-run standard deviation to mean was less than 
an arbitrary threshold of 5%. This analysis showed that N = 5 × 107 incident protons and N = 5 × 106 12C ions is 
sufficient to obtain a satisfactory estimate of thermal neutron fluence (99% probability of the estimated fluence 
being within ±5% of the true fluence).
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Pencil Beam Simulations. The Geant4 simulation and analysis configuration is shown in Fig. 1. 
Monoenergetic beams of protons and 12C ions with a rotationally symmetric 5 mm FWHM Gaussian beam pro-
file were directed perpendicularly towards the surface of a homogeneous PMMA phantom. Four reference pri-
mary beam energies were chosen for the 12C beam, resulting in Bragg peak depths in PMMA of between 45 mm 
and 191 mm. Beam energies were then calculated for the proton beam such that the Bragg peaks were located at 
approximately the same depths. The full set of beam energies for each primary particle type and the correspond-
ing locations of Bragg peaks in each phantom are listed in Table 2. The phantom is a homogeneous 250 mm × 
250 mm × 250 mm cube of PMMA, with physical properties taken from the National Institute of Standards and 
Technology (NIST) database70. PMMA is chosen as the target material as it has a similar electron density and 
hence depth-dose profile to human tissue, and yields a similar range of fragmentation products despite its differ-
ing elemental composition71; moreover, it will be a convenient target for future experimental work.
Pencil beam physical dose and thermal neutron fluence distributions were obtained for each beam type and 
energy, as listed in Table 2, and normalised per primary particle. To estimate dose and neutron fluence distribu-
tions for beam energies which were not simulated (due to the substantial computational cost of performing sim-
ulations for all intermediate energies), an interpolation procedure was performed. Firstly, the expected location 
of the Bragg peak for each intermediate energy was estimated via a 2nd-order polynomial interpolation between 
the locations measured from the dose distributions obtained at each of the four simulated energies. Next, the 
dose and thermal neutron fluence distributions from all but the highest-energy simulation were translated such 
Interaction Energy Range Geant4 Model
Radioactive Decay N/A G4RadioactiveDecayPhysics
Particle Decay N/A G4Decay
Hadron Elastic 0–100 TeV G4HadronElasticPhysicsHP
Ion Inelastic 0–110 MeV Binary Light Ion Cascade
100 MeV–10 GeV QMDModel
9.99 GeV–1 TeV FTFP
Neutron Capture 0–20 MeV NeutronHPCapture
19.9 MeV–100 TeV nRadCapture
Neutron Inelastic 0–20 MeV NeutronHPInelastic
19.9 MeV–9.9 GeV Binary Cascade
Neutron Elastic 0 eV–20 MeV NeutronHPElastic
20 MeV–100 TeV hElasticCHIPS
Proton Inelastic 0–9.9 GeV Binary Cascade
Table 1. Hadron physics models used in all simulations.
Figure 1. The simulation configuration used for pencil beam thermal neutron fluence estimation.
Particle Energies (MeV/u) Depths of Bragg Peaks (mm)
Proton 10C
73.0, 132, 153, 182 38.0, 109, 141, 191
150, 250, 290, 350 45.0, 109, 140, 191
Table 2. Primary energies of the proton and 12C beams applied to the PMMA phantom, and the depth of the 
point of maximum dose deposition (Bragg peak).
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that their Bragg peaks aligned with that of the highest energy simulation, and a 3D spatial interpolation of the 
the dose and neutron fluence distributions for the intermediate energies was performed. Finally, the interpolated 
3D dose and neutron fluence distributions were translated back to the previously-estimated location of the Bragg 
peak for each energy. The result was a library of estimated physical dose distributions and thermal neutron flu-
ence distributions per primary particle for proton and 12C beams, for energies in steps of 1 MeV/u in the range 
73–182 MeV/u for protons and 150–350 MeV/u for 12C. While the method is only an approximation, its accuracy 
can be improved if desired by performing simulations at additional energies in the range of interest.
The library of physical doses distributions deposited by the pencil beams was then converted to biological 
dose; for protons, the relative biological effectiveness factor was assumed to be 1.1, while for 12C it was assumed 
to be 2.5, 3.0 and 3.3 for the pencil beams corresponding to the proximal, centre and the distal edges of the 
spread-out Bragg peak, 1.5 in the entrance plateau and buildup region (defined as the region with a deposited 
dose less than 60% of the maximum value), and a linear interpolation between these values in the intermediate 
regions72–74. The biological dose distributions were then used to develop a simple treatment plan for two target 
volumes for each beam type. These three-dimensional dose distributions for the centred pencil beam at the k th 
energy ( ∈ …k K[1 ]) are denoted BEDctr k, . The corresponding neutron flux is denoted φctr k, .
Estimated Neutron Capture Dose Enhancement. As this study is concerned with determining the 
feasibility of NCEPT rather than evaluating a specific treatment plan, a set of simple treatment plans were devel-
oped for the PMMA target in to estimate the order of neutron capture agent concentration that would be required 
to achieve a 10% increase in photon-equivalent biological dose. For each energy, the BED and thermal neutron 
fluence maps (calculated via the interpolation method previously introduced) are stepped across the transverse 
(xy) plane of the treatment volume corresponding to the Bragg peak depth at each energy, through R row and C 























where BED r c( , )ctr k,  is BEDctr k,  laterally translated so that the centre of the Bragg peak is located at row and column 
r c( , ) in the plane, and φ r c( , )k  is the corresponding neutron fluence. If the desired photon-equivalent dose is D, 
then the objective is to achieve the most uniform approximation of this dose possible within the treatment vol-
ume by determining the number of primary particles Nk required at each energy k which best approximate a flat 

















using an optimisation technique such as Levenberg-Marquardt optimisation, subject to the constraint that Nk 
must be positive. The total number of primary particles required at each energy can then be multiplied by the 
corresponding map of neutron production per primary particle for each energy, to yield a map of total neutron 








The biological dose enhancement resulting from the presence of the neutron capture agent, normally referred to 
as the boron dose in BNCT literature, is estimated using the following relation75:
φσ= ×D N CBEB NCA NCA
where σNCA is the fluence-to-kerma conversion factor (approximately 8.66 × 10−14 for 10B and 9.27 × 10−15 for 
Gd76,77), NNCA is the concentration of neutron capture agent in parts per million, and the the compound biological 
effectiveness CBE = 3.8 for 10B-BPA and ≈40 for the DOTA 157-Gadolinium triphenylphosphonium salt complex 
(based on results of studies in the field of photon activated therapy using the same agent, and correcting for 
expected Auger electron production)76. For this study, the target dose was set to D = 1 GyE, R = C = 11, and steps 
between rows and columns were set to 5 mm (i.e. the same as the FWHM of the beam) for a 50 mm square treat-
ment plane at each energy. A range of energies were selected to extend the spread out Bragg peak (SOBP) between 
depths of 100 mm and 150 mm for the first treatment volume and 140 mm to 190 mm for the second; energies 
were incremented in steps of 1 MeV/u. Therefore, each treatment volume is a 50 mm cubic volume, with 1 GyE of 
dose delivered by the ion beam whilst the remainder of the phantom is regarded as normal tissue.
Reported Neutron Capture Agent Concentrations. A selection of reported clinical and/or preclinical 
tissue concentrations of boron and gadolinium, together with the ratio of concentration in tumours to healthy 
tissue, are listed in Tables 3 and 4, respectively.
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Results
Treatment Plans and Neutron Fluence Distributions. Treatment plans were prepared for each target 
volume for both proton and carbon ion beams. The total number of primary particles at each energy required for 
achieving an average biological dose of 1 GyE across the target volumes were computed, and the 3D dose distri-
butions calculated. The case of carbon-ion irradiation of the shallower treatment volume (at depths ranging from 
100 mm to 150 mm) is shown in Fig. 2.
The per-primary-particle thermal neutron distributions corresponding to each of the energies in the treat-
ment plan were scaled by the number of primary particles determined for each plan and summed for all energies 
required to form the spread out Bragg peak. An example of the resulting distribution of thermal neutron fluence 
(shown as a percentage of the maximum value on the contour maps and additionally as an absolute fluence in the 
3D view) is shown in Fig. 3.
The maximum, mean and minimum thermal neutron fluences obtained within the treatment volumes are 
listed in Table 5.
Required NCA Concentrations. The tumour concentrations of 10B and 157Gd required to achieve a 10% 
increase in biological effective dose are listed in Tables 6 and 7, respectively. The CBEs for each agent are based on 
values estimated in each listed supporting publication.
Normal tissue NCA concentrations are calculated on basis of the tumour concentrations required for a 10% 
increase in biological effective dose and the tumour:normal tissue concentration ratios reported in the literature. 
The maximum additional dose to normal tissue is then determined using this estimate of normal tissue NCA 
concentration together with normal-tissue CBEs reported in the literature and the maximum neutron fluence 
estimated in the normal tissue volume. The maximum percentage increases in dose to normal tissue resulting 
from a 10% increase in biological effective dose in both treatment volumes, are listed for all treatment volumes 
and all evaluated NCAs in Table 8.
Discussion
Several conclusions may be drawn by examining the tumour concentrations of each NCA listed in Tables 6 and 7. 
Firstly, the NCA concentrations required to achieve a 10% increase in biological effective dose in the liver are sub-
stantially lower than those required in the brain for both BPA and BSH, with BPA looking particularly promising 
due to the combination of high CBE and good tumour:normal tissue contrast reported by Suzuki et al.26. On the 
other hand, BSH concentrations have been reported in the literature which would realise a dose boost of close to 
10% - for example, Suzuki et al.78 reported up to 200 and 234 ppm for BSH plus two different embolising agents, 
which would offer dose boosts of the order of 6.4–7.5% in the liver.
The situation is somewhat less positive for the brain; 10B-BPA concentrations required to achieve a 10% 
increase in biological effective dose during proton therapy in the brain would need to be around three times 
greater than the highest concentrations reported in the literature to date, while the concentration needed for 
carbon ion therapy is even greater. Conversely, with the highest BPA concentration reported in the literature of 
125 ppm, the increase in dose is approximately 3.2–3.6% for proton therapy, and about half that for carbon. These 
Reported by Method Compound Target
Concentration 
(PPM) Tumour:normal ratio
Barth et al.16 Intravenous infusion BPA Brain 30 ± 12 5: 1
Luderer et al.80 Convection enhancement BPA Brain 68.3 ± 17.9 8: 1
Alkins et al.23 Ultrasonic enhancement BPA Brain 123 ± 25 6.7: 1
Suzuki et al.78 Inter-arterial infusion BSH + lipidol Liver 200 (6 h) 3.6: 1 (1 h), 14.9: 1 (6 h)
Suzuki et al.78 Inter-arterial infusion BSH + degradable starch microspheres Liver 231 (1 h) 1.4: 1 (1 h), 1.1: 1 (6 h)
Koganei et al.25 Intravenous infusion BSH-encapsulating 10% DSBL liposomes Colon 174 ± 20 1.2: 1–3.5: 1
Table 3. Boron-based neutron capture agent concentrations and the ratios of tumour to healthy tissue 
concentrations reported in the literature.
Reported by Compound Target
Concentration 
(PPM)
De Stasio et al.38 Gd-DOTA GBM (in vitro) 140 (1 h)
Uyen et al.100 Gd-DTPA encapsulated liposome TC-1 (mouse lung endothelium, in vivo) 159
Peters et al.101 Gd-DOTAP liposome F98 & LN229 (glioma, in vitro) 768
Ichikawa et al.102 Gd-DTPA; Chitosan nanoparticles B16F10 (mouse melanoma, in vivo) 1500
Tokumitsu et al.103 Gd-DTPA; Chitosan nanoparticles B16F10 (mouse melanoma, in vivo) 1800
Morrison et al.45 Gd III-triarylphosphonium salts T98G (glioblastoma, in vitro) 3000
Table 4. Gadolinium-based neutron capture agent concentrations reported in the literature. Tumour:normal 
tissue concentration ratios of at least 70 are commonly reported in the literature.
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results do not rule out the use of boron neutron capture agents for NCEPT treatment in the brain, but demon-
strate the need for further development of boron-based NCAs.
Tantalisingly, there are reports in the literature of strong uptake of BPA in the pancreas, an organ in which can-
cer is notoriously difficult to treat79. While there appears to be very little research into BNCT specifically applied 
to the pancreas (particularly on tumour to normal NCA concentration ratios and CBE), it would appear to be a 
good candidate for NCEPT.
Several promising new 10B-based NCAs are still in development80. BSH has been somewhat disappoint-
ing as an NCA in BNCT, chiefly due to its inability to directly penetrate the cell membrane. However, several 
BSH-derived compounds have been proposed that combine up to 8 instances of the BSH compound with peptide 
chains, which are able to penetrate the membrane and deliver high concentrations of boron within the cell. Boron 
concentrations in excess of 5000 ppm have been reported for these compounds81. Other promising recent studies 
have investigated the use of using boron nitride nanotubes as NCAs in BNCT, which can also potentially deliver 
very high 10B concentrations to the tumour82.
For 157Gd, the situation is more complex. The values are highly dependent on how the 157Gd atoms are dis-
tributed; when they are either electrostatically attached to DNA or concentrated in the cell nucleus, the required 
concentrations are well within the ranges reported in the literature; this remains true even when the gadolinium 
is present in the cytoplasm or outside of the cell membrane. Several of the gadolinium compounds now in devel-
opment appear to have many very promising properties for highly selective tumour uptake, and in particular high 
uptake in the nucleus and mitochondria, where they are most effective for neutron capture therapy. Significantly, 
many of the recently developed gadolinium-based compounds appear to offer very high tumour:normal tissue 
concentration ratios.
By comparing the required tumour concentrations obtained in this study to values previously published for 
both boron (up to 231 ppm in the liver26) and gadolinium (up to 3000 ppm in vitro45) it is clear that for certain 
existing combinations of NCA and target tissues, achieving an increase in biologically effective dose of at least 
10% - or, equivalently, reducing the primary radiation dose and hence reducing the radiation dose to normal 
tissue - is feasible.
Additionally, there is also the possibility of further increasing the thermal neutron yield of heavy ion therapy. 
Since the production of neutrons within the target volume is typically considered a nuisance rather than a central 
objective, there has been little research aimed at identifying particular primary species which will result in greater 
rates of thermal neutron production in human tissue targets. We hypothesise that relatively neutron-rich primary 
ion species such as deuterium or helium may increase the thermal neutron yield, and therefore providing a larger 
dose boost via thermal neutron capture than is possible with either protons or carbon ions. This is currently a 
subject of further investigation, with results to be reported in future work.
Regarding the additional dose introduced to healthy tissues resulting from implementation of NCEPT, Table 8 
shows that for most proposed NCAs, the increased dose is quite small compared to the dose boost delivered 
to the tumour (the worst-case scenario being BSH in the liver, due to the relatively low tumour:normal tissue 
Figure 2. Photon-equivalent biological dose, physical dose and primary particle fluence (normalised to the 
total number of primary particles entering the phantom) resulting from 1 GyE carbon ion beam treatment of a 
50 mm × 50 mm × 50 mm volume (100–150 mm depth); discrete beam energies range from 240–300 MeV/u in 
steps of 6 MeV/u). 2D slices and a 3D volume rendering of the dose distribution are also shown.
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Figure 3. Normalised thermal neutron fluence resulting from irradiation of the 100 mm–150 mm target 
volume. Contour lines show fluence as a percentage of the maximum value in the slice, while the colourbars in 
the 3D figures show absolute fluence.
Target 
Depth (mm) Primary Ion




5.96 × 108 7.79 × 108 9.06 ×108
2.86 × 108 3.34 × 108 3.60 × 108
140–190 Proton 12C
6.26 × 108 8.82 × 108 1.09 × 108
3.17 × 108 4.08 × 108 4.68 × 108
Table 5. Thermal neutron fluences obtained for each target volume and treatment plan, assuming a target 
volume average proton or heavy ion biological dose of 1 GyE.
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contrast ratio of 0.3). For a 70 GyE primary ion dose to the tumour (typically delivered over several fractions), if 
the BPA concentration is sufficient to provide an extra 7 Gy tumour dose via NCEPT, the maximum additional 
normal-tissue dose (at the margin of the treatment volume) would be 0.47 GyE in the brain and 1.1 GyE in the 
liver (with 1.8 GyE and 5.2 GyE obtained with BSH in the brain and liver, respectively). For comparison, a BNCT 
treatment plan for glioblastoma multiforme typically delivers a peak dose of 8–14 GyE to normal brain tissue over 
2–3 fractions83.
Intra-tumour and inter-patient tumour heterogeneity resulting in variable biodistribution and pharmacoki-
netics is a major problem in cancer treatments which rely on the targeted delivery of drugs to the malignancy, 
such as chemotherapy, therapeutic nuclear medicine and BNCT84–88. In clinical BNCT, theranostic approaches 
based on the use of radiolabelled or dual boron/gadolinium agents have been proposed to quantify the biodistri-
bution of NCAs via positron emission tomography (PET) or magnetic resonance imaging (MRI) to improve the 
efficacy of neutron capture therapies32,89,90. 18F-BPA, a radio-labelled analogue of 10B-BPA has been successfully 
employed to determine the macrodistribution of boron in the tumour and estimate the tumour to normal tissue 
uptake ratio prior to treatment for treatment planning purposes88,91–95. A similar approach to quantify the biodis-
tribution of the NCAs in target volume is necessary to optimise the treatment delivery in NCEPT.
With the additional dose provided through neutron capture, achievement of a prescribed uniform (or 
non-uniform) total radiation dose (ion plus neutron capture) throughout the tumour volume will require modi-
fications to the treatment planning process. An initial plan can be constructed which only considers the primary 
ion dose. From this, an estimate of the thermal neutron field can be computed. Finally, either by assuming a flat 
distribution of NCA in the tumour, or by measuring it voxel-by-voxel using the theranostic approach mentioned 
previously, the estimated additional dose can be computed, after which the primary dose can be iteratively mod-
ulated until the total dose converges on the desired target dose prescription.
One possible criticism of the NCEPT approach is the need to fractionate the delivery of the therapeutic dose, 
which would either necessitate the use of a NCA with a long residence time or require repeated infusion of the 
NCA. However, the most recent literature recommends delivery of heavy ion radiotherapy via hypofractionation 
(1–2 fractions only)6,96–98. From a practical perspective, this makes addition of a boron-bearing drug infusion 
step to the treatment process a minimal additional burden on the patient, as it may only need to be performed 
once or twice.
As a final observation on the practicality of NCEPT: the main impediment to widespread adoption of neutron 
capture therapy is the limited availability of suitable epithermal neutron sources rather than the availability of 
appropriate NCAs99. NCEPT has the potential to offer a new source of thermal neutrons at any proton or heavy 
ion treatment facility, conveniently situated at the point of treatment inside the patient’s own body. With the pros-
pect of further progress in the development of new NCAs, with greater tumour specificity and potentially very 
Target Depth 
(mm) Primary
10B thermal neutron capture agent concentration (ppm)
BPA (brain)24 BSH (brain)104 BPA (liver)26 BSH (liver)26
RBE = 3.8 RBE = 1.2 RBE = 9.94 RBE = 4.22


















157Gd thermal neutron capture agent concentration (ppm)
Cell36 DNA36 DNA35 MC: DNA31 MC: Cell31
RBE = 5 RBE = 20 RBE = 10 RBE = 12.5 RBE = 1.5


















Table 7. 157Gd concentrations required to obtain a 10% increase in biological effective dose. Estimated values 
are based on published RBEs for non-specific multiple-Auger-electron-emitting nuclei. The right-most columns 
are based on Monte Carlo simulation results31.











0.68 2.60 1.50 7.40 0.14
Table 8. Maximum percentage increase in biological dose delivered to normal tissue, for a 10% increase in 
biological effective dose in the tumour.
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high achievable tumour concentrations, and possibly in combination with ultrasonic or other uptake enhance-
ment methods, it may be possible to achieve even greater dose enhancement in the future.
Conclusion
Our results demonstrate that the thermal neutron fluence distribution resulting from proton and carbon ion 
therapy mostly originates in the vicinity of the Bragg peak (i.e. from a point internal to the treatment volume), 
with the neutron fluence falling with increased distance from the Bragg peak in all directions. The fluence dis-
tribution resulting from a realistic treatment plan is sufficient to enable a significant increase of the order of 10% 
with realistic NCA concentrations of the order of magnitude previously reported in the literature. The resulting 
dose increase in normal tissues is quite modest, and is unlikely to cause additional harm to the patient. To our 
knowledge, this is the first time this concept has been proposed.
Data Availability
The datasets generated and/or analysed during the current study are available from the corresponding author on 
reasonable request.
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